<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diseases</journal-id><journal-id journal-id-type="iso-abbrev">Diseases</journal-id><journal-id journal-id-type="publisher-id">diseases</journal-id><journal-title-group><journal-title>Diseases</journal-title></journal-title-group><issn pub-type="epub">2079-9721</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28943623</article-id><article-id pub-id-type="pmc">5548257</article-id><article-id pub-id-type="doi">10.3390/diseases3040253</article-id><article-id pub-id-type="publisher-id">diseases-03-00253</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Effects of Vitamin D Supplementation on Pulmonary Function of Chronic Obstructive Pulmonary Disease Patients, before and after Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moosavi</surname><given-names>Seyed Ali Javad</given-names></name><xref ref-type="aff" rid="af1-diseases-03-00253">1</xref></contrib><contrib contrib-type="author"><name><surname>Haddadzadeh Shoushtari</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="af2-diseases-03-00253">2</xref><xref rid="c1-diseases-03-00253" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Battino</surname><given-names>Maurizio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-diseases-03-00253"><label>1</label>Department of Pulmonary, Iran University of Medical Sciences; Tehran 14174, Iran; E-Mail: <email>Dr_Moosavi_pul@yahoo.ca</email></aff><aff id="af2-diseases-03-00253"><label>2</label>Department of Pulmonary, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357, Iran</aff><author-notes><corresp id="c1-diseases-03-00253"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>m.haddadzadeh_sh@yahoo.com</email>; Tel.: +98-613-292-1839.</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>4</issue><fpage>253</fpage><lpage>259</lpage><history><date date-type="received"><day>03</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 by the authors.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Vitamin D has several extra calcemic effects. Vitamin D deficiency is highly prevalent in chronic obstructive pulmonary disease (COPD) patients but little is known about it&#x02019;s association with lung function. Objective: To investigate whether supplementation with vitamin D could improve pulmonary function in COPD patients. Design: Before and after, double center, clinical trial. Setting: Hazrat Rasoul University Hospital, Tehran, and Imam Khomaini University Hospital, Ahvaz, Iran. Participants: 24 patients with mild to very severe COPD. Intervention: Loading dose of 300,000&#x02013;600,000 International Units (IU) of vitamin D, then 50000 IU weekly for 12 weeks. Measurements: The outcomes included forced expiratory volume in one second (FEV1), forced vital capacity (FVC), vital capacity (VC), forced expiratory flow between 25%&#x02013;75% of forced vital capacity (FEF 25%&#x02013;75%), exercise capacity according to the six minute walk test(6MWT) and the saturation of oxygen during exercise. Results: The mean FEV1 (<italic>p</italic>-value = 0.866), FVC (<italic>p</italic>-value = 0.475) and VC (<italic>p</italic>-value = 0.425) were not significantly different before and after intervention. FEF 25%&#x02013;75% did not improve with this intervention (<italic>p</italic>-value = 0.555). The vitamin D supplementation did not have any significant effect on the exercise capacity (<italic>p</italic>-value=0.175) or the saturation of oxygen (<italic>p</italic>-value = 0.635). Conclusion: Pulmonary function and exercise capacity did not improve with vitamin D supplementation in COPD patients.</p></abstract><kwd-group><kwd>chronic obstructive pulmonary disease</kwd><kwd>vitamin D</kwd></kwd-group></article-meta></front><body><sec id="sec1-diseases-03-00253"><title>1. Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation due to inhalation of noxious particles or gases such as cigarette smoke. Airway inflammation is prominent in COPD [<xref rid="B1-diseases-03-00253" ref-type="bibr">1</xref>]. With disease progression, FEV1 declines [<xref rid="B2-diseases-03-00253" ref-type="bibr">2</xref>]. No treatment has been proven to inhibit COPD progression except smoking cessation [<xref rid="B3-diseases-03-00253" ref-type="bibr">3</xref>].</p><p>Vitamin D and parathyroid hormone are the regulators of calcium and phosphate but low concentration of vitamin D is associated with many diseases other than osteoporosis, including hypertension, ischemic heart diseases, type I diabetes, cancer, autoimmune diseases and infections. Also, there are significant associations between vitamin D status and death caused by diseases of the respiratory system, the digestive system, and endocrine, nutritional and metabolic diseases [<xref rid="B4-diseases-03-00253" ref-type="bibr">4</xref>,<xref rid="B5-diseases-03-00253" ref-type="bibr">5</xref>,<xref rid="B6-diseases-03-00253" ref-type="bibr">6</xref>,<xref rid="B7-diseases-03-00253" ref-type="bibr">7</xref>,<xref rid="B8-diseases-03-00253" ref-type="bibr">8</xref>,<xref rid="B9-diseases-03-00253" ref-type="bibr">9</xref>,<xref rid="B10-diseases-03-00253" ref-type="bibr">10</xref>,<xref rid="B11-diseases-03-00253" ref-type="bibr">11</xref>,<xref rid="B12-diseases-03-00253" ref-type="bibr">12</xref>,<xref rid="B13-diseases-03-00253" ref-type="bibr">13</xref>].</p><p>There are some associations between vitamin D deficiency and COPD. Skaaby <italic>et al.</italic> reported an inverse association between vitamin D deficiency and COPD and vitamin D deficiency is present in 60% to 75% of patients with severe COPD [<xref rid="B14-diseases-03-00253" ref-type="bibr">14</xref>,<xref rid="B15-diseases-03-00253" ref-type="bibr">15</xref>].</p><p>There is a strong relationship between serum concentration of 25-hydroxyvitamin D and FEV1 and FVC [<xref rid="B16-diseases-03-00253" ref-type="bibr">16</xref>], but to the best of our knowledge there are few studies that have evaluated the effect of vitamin D supplementation on the improvement of lung function in COPD patients.</p><p>The aim of this study is to investigate the role of vitamin D supplementation in improving lung function, exercise capacity and the saturation of oxygen during exercise in COPD patients.</p></sec><sec id="sec2-diseases-03-00253"><title>2. Method and Materials</title><p>Our study was a before and after clinical trial. Eligible patients were current or ex-smokers or were exposed to noxious inhalents, and had a diagnosis of COPD according to the Global Initiative for chronic obstructive Lung Disease (GOLD) definition. They had no history of renal stone or renal failure or other diseases that interact with vitamin D metabolism and did not take vitamin D or calcium supplements. They had no recent history of exacerbation before inclusion.</p><p>Baseline characteristics included serum levels of 25-hydroxy vitamin D, severity of airflow obstruction, six-minute walk test, and O2 saturation. We excluded patients who needed continued oxygen therapy during exercise, because we did not have suitable portable oxygen for continues oxygen therapy during 6MWT.The spirometery was performed before and after intervention with a standard spirometer (Ganshorn Company, Niederlauer, Germany).</p><p>If the patients had a low level of serum 25-hydroxyvitamin D, they took a loading dose of 300,000 of vitamin D for insufficient (&#x0003c;30 ng/mL) and 600,000 IU for deficient (&#x0003c;20 ng/mL) levels intramuscularly and all patients took 50,000 IU weekly for 12 weeks per oral [<xref rid="B17-diseases-03-00253" ref-type="bibr">17</xref>,<xref rid="B18-diseases-03-00253" ref-type="bibr">18</xref>]. The serum level of vitamin D was checked afterwards and all of the variables were tested again. We evaluated hyper calcuria only in toxic levels of vitamin D (more than 80 ng/mL) [<xref rid="B19-diseases-03-00253" ref-type="bibr">19</xref>]. The patients were excluded from the study if they did not want to continue the treatment or were noncompliant.</p></sec><sec id="sec3-diseases-03-00253"><title>3. Statistical Analysis</title><p>We calculated the sample size with consideration of &#x003b1; = 0.05 and &#x003b2; = 0.8. A total of 18 patients were needed for rich statistically significant results. The included patients were 24. One patient died before termination of trial because of severe multi lobar pneumonia. Twenty-three patients continued the study. Paired sample t-test was used to analyze the results.</p><p>The patients provided written, informed consent. The study was approved by the local ethics committee of the Iran University of Medical Sciences and registered with Iranian Clinical Trails Center (NCT 2015012720828N1).</p></sec><sec id="sec4-diseases-03-00253"><title>4. Results</title><p>A total of 59 participants aged 35 to 78 years participated in this study. Forty-two patients had insufficient or deficient levels of 25-hydroxyvitamin D. We were able to follow 23 of them to initiate supplementation. The mean age of patients was 62 (SD = 12). Three patients were not cigarette smokers: one was a female water pipe smoker and the two others were exposed to noxious inhalants.</p><p>One of the patients was in mild stage, eight in moderate stage,13 in severe and one in very severe stage of COPD. The mean serum level of vitamin D was 14 ng/mL (SD = 5) (<xref ref-type="table" rid="diseases-03-00253-t001">Table 1</xref>).</p><table-wrap id="diseases-03-00253-t001" position="float"><object-id pub-id-type="pii">diseases-03-00253-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Men, <italic>n(%)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">20 (83)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean age (SD), <italic>y</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">64 (11)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><bold>GOLD stage, <italic>n(%)</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean 25(OH) vit D</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">level (SD), ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><p>Paired sample t-test analysis showed no significant differences before and after supplementation between FEV1 (<italic>p</italic>-value = 0.866), FVC (<italic>p</italic>-value=0.475), VC (<italic>p</italic>-value = 0.425) and FEF 25%&#x02013;75% (<italic>p</italic>-value = 0.555; <xref ref-type="table" rid="diseases-03-00253-t002">Table 2</xref>) (<xref ref-type="fig" rid="diseases-03-00253-f001">Figure 1</xref>).</p><p>The mean distance that participants walked during 6MWT was 350 meters before and 360 meters after vitamin D supplementation, which was not significantly different (<italic>p</italic>-value = 0.175). The saturation of oxygen during 6MWT did not improve with supplementation.</p><table-wrap id="diseases-03-00253-t002" position="float"><object-id pub-id-type="pii">diseases-03-00253-t002_Table 2</object-id><label>Table 2</label><caption><p>End points.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean &#x000b1; SD<break/>(Before)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean &#x000b1; SD<break/>(After)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">FEV1</td><td align="center" valign="middle" rowspan="1" colspan="1">52% &#x000b1; 17%</td><td align="center" valign="middle" rowspan="1" colspan="1">52% &#x000b1; 17%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.866</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FVC</td><td align="center" valign="middle" rowspan="1" colspan="1">67% &#x000b1; 17%</td><td align="center" valign="middle" rowspan="1" colspan="1">69% &#x000b1; 20%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.475</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VC</td><td align="center" valign="middle" rowspan="1" colspan="1">67% &#x000b1; 17%</td><td align="center" valign="middle" rowspan="1" colspan="1">68% &#x000b1; 16%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.452</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FEF 25%&#x02013;75%</td><td align="center" valign="middle" rowspan="1" colspan="1">27% &#x000b1; 15%</td><td align="center" valign="middle" rowspan="1" colspan="1">28% &#x000b1; 14%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.555</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6MWT, m</td><td align="center" valign="middle" rowspan="1" colspan="1">350</td><td align="center" valign="middle" rowspan="1" colspan="1">360</td><td align="center" valign="middle" rowspan="1" colspan="1">0.175</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O2 Sat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% &#x000b1; 1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95% &#x000b1; 1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.635</td></tr></tbody></table></table-wrap><fig id="diseases-03-00253-f001" position="float"><label>Figure 1</label><caption><p>Means of FEV1 (<bold>A</bold>), FVC (<bold>B</bold>), VC (<bold>C</bold>) and FEF 25%&#x02013;75% (<bold>D</bold>) before and after supplementation.</p></caption><graphic xlink:href="diseases-03-00253-g001"/></fig></sec><sec id="sec5-diseases-03-00253"><title>5. Discussion</title><p>The purpose of this study was to evaluate the role of correction of serum vitamin D level on the pulmonary function of COPD patients. We could not show any effect of this intervention.</p><p>A cross-sectional study by Peter N. Black and Robert Scragg reported a relationship between serum 25-hydroxyvitamin D and FEV1 and FVC but there was no difference in the FEV1/FVC ratio between the highest and lowest quintiles of serum level of vitamin D. In spite of a greater difference in FEV1 between the highest and lowest quintiles of vitamin D in those with diagnosis of chronic bronchitis or emphysema than for other participants, the interaction between the diagnosis and the serum vitamin D was not significant [<xref rid="B16-diseases-03-00253" ref-type="bibr">16</xref>].</p><p>This study had comparable results with a randomized clinical trial by A. Lehouck <italic>et al.</italic> [<xref rid="B20-diseases-03-00253" ref-type="bibr">20</xref>]. The main goal of their study was the reduction of COPD exacerbation with a high dose of vitamin D. The annual rate of exacerbation in their study was 2.8. Frequent exacerbations may be associated with a more rapid decline of FEV1 [<xref rid="B21-diseases-03-00253" ref-type="bibr">21</xref>] and may interfere with the likely effect of vitamin D supplementation on pulmonary function. Also, most of our participants were screened during outpatient visits and did not have exacerbation long before their inclusion and most of them had no history of hospitalization for COPD exacerbation before and during the study. Only one of our patients had exacerbation at the initiation of the study. However, we used a higher dose of vitamin D supplementation. In fact, there are some suggestions that higher doses of vitamin D are required to increase serum25-hydroxyvitamin D levels, which may be needed for extra calcemic effects [<xref rid="B22-diseases-03-00253" ref-type="bibr">22</xref>,<xref rid="B23-diseases-03-00253" ref-type="bibr">23</xref>].</p><p>The result of a cohort study by K.M. Kunisaki <italic>et al.</italic> supports our study [<xref rid="B24-diseases-03-00253" ref-type="bibr">24</xref>].Their cases and controls were continued smokers with rapid and slow lung function decline respectively. The baseline serum 25-hydroxy vitamin D levels were not predictive of subsequent lung function decline in a six-year follow up. Moreover, the results of some trials of vitamin D supplementation on its effect in other chronic diseases have been disappointing [<xref rid="B25-diseases-03-00253" ref-type="bibr">25</xref>].</p><p>There are some hypotheses for these results. There are several mechanisms of action from vitamin D in COPD: (1) calcemic effects; (2) lung tissue remodeling effects; (3) antimicrobial effects; (4) immune modulation effects; and (5) peripheral muscle function effects.</p><p>The calcemic effect of vitamin D on the pulmonary function is related to its kyphosis effect, and its reversal needs a long time period in order to allow for lung tissue remodeling. Therefore, the short term follow up period of our study could not evaluate the vitamin D effects on these mechanisms.</p><p>The absence of the immune modulatory effect of vitamin D may be due to the obstruction of small and larger airways in COPD, which is associated with the remodeling process, and seems to be irreversible. The presence of airway obstruction in the absence of accumulation of some type of inflammatory cells in stage 3 and 4 of COPD despite a cessation of smoking nine years earlier supports this idea [<xref rid="B1-diseases-03-00253" ref-type="bibr">1</xref>].</p><p>There were no significant differences in saturation of oxygen during exercise before and after vitamin D supplementation. This may be confounded by the exclusion of hypoxemic patients for the reason we described. Also, the mean distances that the patients could walk after the intervention were not longer, which supports the results of previous similar studies in heart failure patients [<xref rid="B21-diseases-03-00253" ref-type="bibr">21</xref>,<xref rid="B23-diseases-03-00253" ref-type="bibr">23</xref>].</p><p>Our study had limitations. One was small sample size. In addition, this study was a before and after study. In this type of studies, the intervention is confounded by the Hawthrone effect. This effect can lead to an overestimation of the effectiveness of an intervention. However, we could not show any effect of our intervention and it seems that our results were not confounded by this effect.</p><p>The technique of doing 6MWT did not fulfill the ATS guidelines. We did not use the Borg scale of dyspnea and the only end point in this test was the distance that the patient walked without severe dyspnea in his or her sense. Only one of our patients could not continue the test and stopped because of dyspnea.</p><p>The other limitation was the short follow up period. Some of our patients were from other cities, or were from villages and we had difficulties with maintaining the study follow up. We believe the likely mechanisms of effect of vitamin D on the outcomes which we described would probably not have prevented us from arriving at our end points in the short follow up period.</p><p>In conclusion, a high dose of vitamin D supplementation had no effects on the improvement of pulmonary function and the exercise capacity of COPD patients.</p></sec></body><back><ack><title>Acknowledgment</title><p>We would like to thank our colleagues Amir Jamshidnezhad and Mohammadreza Akhond for their assistance in this article.</p></ack><notes><title>Author Contributions</title><p>Seied Ali Javad Moosavi and Maryam Haddadzadeh Shoushtari, performed the experimental work; Maryam Haddadzadeh Shoushtari wrote the manuscript. All authors discussed, edited and approved the final version.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-diseases-03-00253"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hogg</surname><given-names>J.C.</given-names></name><name><surname>Chu</surname><given-names>F.</given-names></name><name><surname>Utokaparch</surname><given-names>S.</given-names></name><name><surname>Woods</surname><given-names>R.</given-names></name><name><surname>Elliott</surname><given-names>W.M.</given-names></name><name><surname>Buzatu</surname><given-names>L.</given-names></name><name><surname>Cherniack</surname><given-names>R.M.</given-names></name><name><surname>Rogers</surname><given-names>R.M.</given-names></name><name><surname>Sciurba</surname><given-names>F.C.</given-names></name><name><surname>Coxson</surname><given-names>H.O.</given-names></name><etal/></person-group>
<article-title>The nature of small-airway obstruction in chronic obstructive pulmonary disease</article-title>
<source>N. Engl. J. Med.</source>
<year>2004</year>
<volume>350</volume>
<fpage>2645</fpage>
<lpage>2653</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa032158</pub-id>
<pub-id pub-id-type="pmid">15215480</pub-id></element-citation></ref><ref id="B2-diseases-03-00253"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>G.C.</given-names></name><name><surname>Seemungal</surname><given-names>T.A.</given-names></name><name><surname>Bhowmik</surname><given-names>A.</given-names></name><name><surname>Wedzicha</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</article-title>
<source>Thorax</source>
<year>2002</year>
<volume>57</volume>
<fpage>847</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="doi">10.1136/thorax.57.10.847</pub-id>
<pub-id pub-id-type="pmid">12324669</pub-id></element-citation></ref><ref id="B3-diseases-03-00253"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>N.R.</given-names></name><name><surname>Skeans</surname><given-names>M.A.</given-names></name><name><surname>Wise</surname><given-names>R.A.</given-names></name><name><surname>Manfreda</surname><given-names>J.</given-names></name><name><surname>Kanner</surname><given-names>R.E.</given-names></name><name><surname>Connett</surname><given-names>J.E.</given-names></name><collab>Lung Health Study Research Group</collab></person-group>
<article-title>The effects of a smoking cessation intervention on 14.5-year mortality, a randomized clinical trial</article-title>
<source>Ann. Intern. Med.</source>
<year>2005</year>
<volume>142</volume>
<fpage>233</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-142-4-200502150-00005</pub-id>
<pub-id pub-id-type="pmid">15710956</pub-id></element-citation></ref><ref id="B4-diseases-03-00253"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>C.R.</given-names></name><name><surname>Arum</surname><given-names>S.M.</given-names></name><name><surname>Smith</surname><given-names>C.M.</given-names></name></person-group>
<article-title>Vitamin D deficiency and chronic lung disease</article-title>
<source>Can. Respir. J.</source>
<year>2009</year>
<volume>16</volume>
<fpage>75</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">19557213</pub-id></element-citation></ref><ref id="B5-diseases-03-00253"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Etten</surname><given-names>E.</given-names></name><name><surname>Mathieu</surname><given-names>M.C.</given-names></name></person-group>
<article-title>Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts</article-title>
<source>J. Steroid Biochem. Mol. Biol.</source>
<year>2005</year>
<volume>97</volume>
<fpage>93</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsbmb.2005.06.002</pub-id>
<pub-id pub-id-type="pmid">16046118</pub-id></element-citation></ref><ref id="B6-diseases-03-00253"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baeke</surname><given-names>F.</given-names></name><name><surname>van Etten</surname><given-names>E.</given-names></name><name><surname>Gysemans</surname><given-names>C.</given-names></name><name><surname>Overbergh</surname><given-names>L.</given-names></name><name><surname>Mathieu</surname><given-names>C.</given-names></name></person-group>
<article-title>Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities</article-title>
<source>Mol. Aspects Med.</source>
<year>2008</year>
<volume>29</volume>
<fpage>376</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1016/j.mam.2008.05.004</pub-id>
<pub-id pub-id-type="pmid">18621414</pub-id></element-citation></ref><ref id="B7-diseases-03-00253"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bischoff-Ferrari</surname><given-names>H.A.</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B.</given-names></name><name><surname>Willett</surname><given-names>W.C.</given-names></name><name><surname>Staehelin</surname><given-names>H.B.</given-names></name><name><surname>Bazemore</surname><given-names>M.G.</given-names></name><name><surname>Zee</surname><given-names>R.Y.</given-names></name><name><surname>Wong</surname><given-names>J.B.</given-names></name></person-group>
<article-title>Effect of Vitamin D on falls: A meta-analysis</article-title>
<source>JAMA</source>
<year>2004</year>
<volume>291</volume>
<fpage>1999</fpage>
<lpage>2006</lpage>
<pub-id pub-id-type="doi">10.1001/jama.291.16.1999</pub-id>
<pub-id pub-id-type="pmid">15113819</pub-id></element-citation></ref><ref id="B8-diseases-03-00253"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ginde</surname><given-names>A.A.</given-names></name><name><surname>Mansbach</surname><given-names>J.M.</given-names></name><name><surname>Camargo</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey</article-title>
<source>Arch. Intern. Med.</source>
<year>2009</year>
<volume>169</volume>
<fpage>384</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1001/archinternmed.2008.560</pub-id>
<pub-id pub-id-type="pmid">19237723</pub-id></element-citation></ref><ref id="B9-diseases-03-00253"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kriegel</surname><given-names>M.A.</given-names></name><name><surname>Manson</surname><given-names>J.E.</given-names></name><name><surname>Costenbader</surname><given-names>K.H.</given-names></name></person-group>
<article-title>Does vitamin D affect risk of developing autoimmune disease?: A systematic review</article-title>
<source>Semin. Arthritis Rheum.</source>
<year>2011</year>
<volume>40</volume>
<fpage>512</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1016/j.semarthrit.2010.07.009</pub-id>
<pub-id pub-id-type="pmid">21047669</pub-id></element-citation></ref><ref id="B10-diseases-03-00253"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>A.V.</given-names></name><name><surname>Trump</surname><given-names>D.L.</given-names></name><name><surname>Johnson</surname><given-names>C.S.</given-names></name><name><surname>Feldman</surname><given-names>D.</given-names></name></person-group>
<article-title>The role of vitamin D in cancer prevention and treatment</article-title>
<source>Endocrinol. Metab. Clin. North Am.</source>
<year>2010</year>
<volume>39</volume>
<fpage>401</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1016/j.ecl.2010.02.011</pub-id>
<pub-id pub-id-type="pmid">20511060</pub-id></element-citation></ref><ref id="B11-diseases-03-00253"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nnoaham</surname><given-names>K.E.</given-names></name><name><surname>Clarke</surname><given-names>A.</given-names></name></person-group>
<article-title>Low serum vitamin D levels and tuberculosis, a systematic review and meta-analysis</article-title>
<source>Int. J. Epidemiol.</source>
<year>2008</year>
<volume>37</volume>
<fpage>113</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1093/ije/dym247</pub-id>
<pub-id pub-id-type="pmid">18245055</pub-id></element-citation></ref><ref id="B12-diseases-03-00253"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.J.</given-names></name><name><surname>Pencina</surname><given-names>M.J.</given-names></name><name><surname>Booth</surname><given-names>S.L.</given-names></name><name><surname>Jacques</surname><given-names>P.F.</given-names></name><name><surname>Ingelsson</surname><given-names>E.</given-names></name><name><surname>Lanier</surname><given-names>K.</given-names></name><name><surname>Benjamin</surname><given-names>E.J.</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>R.B.</given-names></name><name><surname>Wolf</surname><given-names>M.</given-names></name><name><surname>Vasan</surname><given-names>R.S.</given-names></name></person-group>
<article-title>Vitamin D deficiency and risk of cardiovascular disease</article-title>
<source>Circulation</source>
<year>2008</year>
<volume>117</volume>
<fpage>503</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.706127</pub-id>
<pub-id pub-id-type="pmid">18180395</pub-id></element-citation></ref><ref id="B13-diseases-03-00253"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skaaby</surname><given-names>T.</given-names></name><name><surname>Husemoen</surname><given-names>L.L.</given-names></name><name><surname>Pisinger</surname><given-names>C.</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>T.</given-names></name><name><surname>Thuesen</surname><given-names>B.H.</given-names></name><name><surname>Fenger</surname><given-names>M.</given-names></name><name><surname>Linneberg</surname><given-names>A.</given-names></name></person-group>
<article-title>Vitamin D status and chronic obstructive pulmonary disease: A prospective general population study</article-title>
<source>PLoS ONE</source>
<year>2014</year>
<volume>9</volume>
<fpage>e90654</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0090654</pub-id>
<pub-id pub-id-type="pmid">24594696</pub-id></element-citation></ref><ref id="B14-diseases-03-00253"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skaaby</surname><given-names>T.</given-names></name><name><surname>Husemoen</surname><given-names>L.L.</given-names></name><name><surname>Pisinger</surname><given-names>C.</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>T.</given-names></name><name><surname>Thuesen</surname><given-names>B.H.</given-names></name><name><surname>Fenger</surname><given-names>M.</given-names></name><name><surname>Linneberg</surname><given-names>A.</given-names></name></person-group>
<article-title>Vitamin D status and cause-specific mortality: A general population study</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<fpage>e52423</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0052423</pub-id>
<pub-id pub-id-type="pmid">23285034</pub-id></element-citation></ref><ref id="B15-diseases-03-00253"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janssens</surname><given-names>W.</given-names></name><name><surname>Bouillon</surname><given-names>R.</given-names></name><name><surname>Claes</surname><given-names>B.</given-names></name><name><surname>Carremans</surname><given-names>C.</given-names></name><name><surname>Lehouck</surname><given-names>A.</given-names></name><name><surname>Buysschaert</surname><given-names>I.</given-names></name><name><surname>Coolen</surname><given-names>J.</given-names></name><name><surname>Mathieu</surname><given-names>C.</given-names></name><name><surname>Decramer</surname><given-names>M.</given-names></name><name><surname>Lambrechts</surname><given-names>D.</given-names></name></person-group>
<article-title>Vitamin D deficiency is highly prevalent in COPD and correlates withvariants in the vitamin D-binding gene</article-title>
<source>Thorax</source>
<year>2010</year>
<volume>65</volume>
<fpage>215</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1136/thx.2009.120659</pub-id>
<pub-id pub-id-type="pmid">19996341</pub-id></element-citation></ref><ref id="B16-diseases-03-00253"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Black</surname><given-names>P.N.</given-names></name><name><surname>Scragg</surname><given-names>R.</given-names></name></person-group>
<article-title>Relationship between serum 25-Hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey</article-title>
<source>Chest</source>
<year>2005</year>
<volume>128</volume>
<fpage>3792</fpage>
<lpage>3798</lpage>
<pub-id pub-id-type="doi">10.1378/chest.128.6.3792</pub-id>
<pub-id pub-id-type="pmid">16354847</pub-id></element-citation></ref><ref id="B17-diseases-03-00253"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pearce</surname><given-names>S.H.</given-names></name><name><surname>Cheetham</surname><given-names>T.D.</given-names></name></person-group>
<article-title>Diagnosis and management of vitamin D deficiency</article-title>
<source>BMJ</source>
<year>2010</year>
<volume>340</volume>
<pub-id pub-id-type="doi">10.1136/bmj.b5664</pub-id>
<pub-id pub-id-type="pmid">20064851</pub-id></element-citation></ref><ref id="B18-diseases-03-00253"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R.</given-names></name><name><surname>Bischoff-Ferrari</surname><given-names>H.</given-names></name><name><surname>Boucher</surname><given-names>B.J.</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B.</given-names></name><name><surname>Garland</surname><given-names>C.F.</given-names></name><name><surname>Heaney</surname><given-names>R.P.</given-names></name><name><surname>Holick</surname><given-names>M.F.</given-names></name><name><surname>Hollis</surname><given-names>B.W.</given-names></name><name><surname>Lamberg-Allardt</surname><given-names>C.</given-names></name><name><surname>McGrath</surname><given-names>J.J.</given-names></name><etal/></person-group>
<article-title>The urgent need to recommend an intake of vitamin D that is effective</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2007</year>
<volume>85</volume>
<fpage>649</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="pmid">17344484</pub-id></element-citation></ref><ref id="B19-diseases-03-00253"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R.</given-names></name></person-group>
<article-title>Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety</article-title>
<source>Am. J. Nutr.</source>
<year>1999</year>
<volume>69</volume>
<fpage>842</fpage>
<lpage>856</lpage>
</element-citation></ref><ref id="B20-diseases-03-00253"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lehouck</surname><given-names>A.</given-names></name><name><surname>Mathieu</surname><given-names>C.</given-names></name><name><surname>Carremans</surname><given-names>C.</given-names></name><name><surname>Baeke</surname><given-names>F.</given-names></name><name><surname>Verhaegen</surname><given-names>J.</given-names></name><name><surname>Van Eldere</surname><given-names>J.</given-names></name><name><surname>Decallonne</surname><given-names>B.</given-names></name><name><surname>Bouillon</surname><given-names>R.</given-names></name><name><surname>Decramer</surname><given-names>M.</given-names></name><name><surname>Janssens</surname><given-names>W.</given-names></name></person-group>
<article-title>High doses vitamin D to reduce exacerbations in chronic obstructive pulmonary disease</article-title>
<source>Ann. Intern. Med.</source>
<year>2012</year>
<volume>156</volume>
<fpage>105</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-156-2-201201170-00004</pub-id>
<pub-id pub-id-type="pmid">22250141</pub-id></element-citation></ref><ref id="B21-diseases-03-00253"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A.</given-names></name></person-group>
<article-title>Impact of exacerbations on COPD</article-title>
<source>Eur. Respir. Rev.</source>
<year>2010</year>
<volume>19</volume>
<fpage>113</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1183/09059180.00002610</pub-id>
<pub-id pub-id-type="pmid">20956179</pub-id></element-citation></ref><ref id="B22-diseases-03-00253"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bischoff-Ferrari</surname><given-names>H.A.</given-names></name><name><surname>Giovannucci</surname><given-names>E.</given-names></name><name><surname>Willett</surname><given-names>W.C.</given-names></name><name><surname>Dietrich</surname><given-names>T.</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B.</given-names></name></person-group>
<article-title>Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2006</year>
<volume>84</volume>
<fpage>18</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">16825677</pub-id></element-citation></ref><ref id="B23-diseases-03-00253"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieth</surname><given-names>R.</given-names></name></person-group>
<article-title>Vitamin D toxicity, policy, and science</article-title>
<source>J Bone Miner. Res.</source>
<year>2007</year>
<volume>22</volume>
<fpage>64</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1359/jbmr.07s221</pub-id>
<pub-id pub-id-type="pmid">17042715</pub-id></element-citation></ref><ref id="B24-diseases-03-00253"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kunisaki</surname><given-names>K.M.</given-names></name><name><surname>Niewoehner</surname><given-names>D.E.</given-names></name><name><surname>Singh</surname><given-names>R.J.</given-names></name><name><surname>Connett</surname><given-names>J.E.</given-names></name></person-group>
<article-title>Vitamin D status and longitudinal lung function decline in the Lung Health Study</article-title>
<source>Eur. Respir. J.</source>
<year>2011</year>
<volume>37</volume>
<fpage>238</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1183/09031936.00146509</pub-id>
<pub-id pub-id-type="pmid">20595151</pub-id></element-citation></ref><ref id="B25-diseases-03-00253"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Witham</surname><given-names>M.D.</given-names></name><name><surname>Crighton</surname><given-names>L.J.</given-names></name><name><surname>Gillespie</surname><given-names>N.D.</given-names></name><name><surname>Struthers</surname><given-names>A.D.</given-names></name><name><surname>McMurdo</surname><given-names>M.E.</given-names></name></person-group>
<article-title>The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: A randomized controlled trial</article-title>
<source>Circ. Heart Fail.</source>
<year>2010</year>
<volume>3</volume>
<fpage>195</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.109.907899</pub-id>
<pub-id pub-id-type="pmid">20103775</pub-id></element-citation></ref></ref-list></back></article>